Tung-Wei Hsu
Overview
Explore the profile of Tung-Wei Hsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
44
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hsu T, Wang W, Chen H, Wang T, Su C, Liao P, et al.
Cancer Metab
. 2025 Feb;
13(1):7.
PMID: 39930542
Background: Lactate dehydrogenase A (LDHA) can regulate tumorigenesis and cancer progression. Nevertheless, whether the regulation of LDHA is involved in the development of gemcitabine resistance in PDAC has not yet...
2.
Hsu T, Wang W, Chen A, Chiu C, Liao P, Chen H, et al.
J Cell Physiol
. 2024 Aug;
239(12):e31416.
PMID: 39164986
Pancreatic cancer has one of the highest fatality rates and the poorest prognosis among all cancer types worldwide. Gemcitabine is a commonly used first-line therapeutic drug for pancreatic cancer; however,...
3.
Yeh Y, Hsu T, Su Y, Wang C, Liao P, Chiu C, et al.
Aging (Albany NY)
. 2023 Nov;
15(22):12873-12889.
PMID: 37976135
Dacarbazine (DTIC) is the primary first-line treatment for advanced-stage metastatic melanoma; thus, DTIC resistance is poses a major challenge. Therefore, investigating the mechanism underlying DTIC resistance must be investigated. Dicer,...
4.
Hsu T, Su Y, Chen H, Liao P, Shen S, Tsai K, et al.
Aging (Albany NY)
. 2023 Jul;
15(13):6503-6525.
PMID: 37433225
Sorafenib, a small-molecule inhibitor targeting several tyrosine kinase pathways, is the standard treatment for advanced hepatocellular carcinoma (HCC). However, not all patients with HCC respond well to sorafenib, and 30%...
5.
Su C, Hsu T, Chen H, Wang W, Huang C, Hung C, et al.
J Cell Physiol
. 2023 Feb;
238(4):829-841.
PMID: 36815383
Metastasis in breast cancer usually lead to the majority of deaths on clinical patients. Accordingly, diagnosis of metastasis at the early stage in breast cancer is important to improve the...
6.
Park J, Peng J, Shen Y, Lin C, Hsu T, Su Y, et al.
Mol Metab
. 2022 Aug;
65:101576.
PMID: 35995401
Objective: Dicer is an enzyme that processes microRNAs (miRNAs) precursors into mature miRNAs, which have been implicated in various aspects of cancer progressions, such as clinical aggressiveness, prognosis, and survival...
7.
Hsu T, Chen H, Liao P, Su Y, Chiu C, Huang C, et al.
Aging (Albany NY)
. 2022 Aug;
14(16):6520-6536.
PMID: 35951366
Distant metastasis is the leading cause of death in patients with breast cancer. Despite considerable treatment advances, the clinical outcomes of patients with metastatic breast cancer remain poor. CSCs can...
8.
Su C, Hsu T, Sung S, Huang M, Chen K, Huang C, et al.
Environ Toxicol
. 2021 Mar;
36(7):1278-1287.
PMID: 33734566
AXL which is a chemosensitizer protein for breast cancer cells in response to epidermal growth factor receptor-tyrosine kinase inhibitor and suppresses tumor growth. The clinical information show nuclear factor I...
9.
Su Y, Hsu T, Chen H, Su C, Huang M, Chuang T, et al.
J Cell Physiol
. 2020 Nov;
236(6):4420-4434.
PMID: 33184874
Gemcitabine has been a commonly used therapeutic agent for treatment of pancreatic cancer. In the clinic, a growing resistance to gemcitabine has been observed in patients with pancreatic cancer, and...
10.
Hseu Y, Hsu T, Lin H, Chen C, Chen S
Food Chem Toxicol
. 2017 Mar;
103:253-260.
PMID: 28302478
Dicrotophos (Dic), an insecticide and acaricide, is used against a variety of sucking, boring and chewing pests. It was proven that Dic induced oxidative DNA damage in HepG2 cells. However,...